MyFinsight
Home
Blog
About
Contact
Download
Download image
Unrealized gain (loss) on
marketable securities
$225K
Total comprehensive
loss
-$166,083K
Total other
comprehensive gain (loss)
$225K
Net loss
-$166,308K
Interest and investment
income
$11,226K
Operating loss
-$177,534K
Total operating
expenses
$177,534K
Research and development
$153,351K
General and
administrative
$24,183K
Back
Back
Income Statement
source: myfinsight.com
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)